Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
Parps show more promise in ovarian and prostate cancers, but Kras disappoints. Here's a round up of Vantage's coverage of the 2019 European Society for Medical…
In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?